Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CanTreatCOVID: Adaptive Platform for COVID-19 Therapeutics
NCT05614349Phase 3Active, not recruiting
- Sponsor
- Unity Health Toronto
- Start
- Jan 2023
- Primary completion
- Apr 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Nirmatrelvir, selenium, zinc, lycopene, ascorbic acid in coronavirus disease 2019 (COVID-19), sponsored by Unity Health Toronto. Started Jan 2023; status: active, not recruiting.
02
Drugs
Nirmatrelvirseleniumzinclycopeneascorbic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05614349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614349.